Pediatric Urinary Tract Infection 

  • Author: Donna J Fisher, MD; Chief Editor: Russell W Steele, MD   more...
 
Updated: Feb 16, 2012
 

Background

Urinary tract infection (UTI) is one of the most common pediatric infections. It distresses the child, concerns the parents, and may cause permanent kidney damage. The 2 broad clinical categories of UTI are pyelonephritis (upper UTI) and cystitis (lower UTI).

The most common causative organisms are bowel flora, typically gram-negative rods. Escherichia coli is the most commonly isolated organism from pediatric patients with UTIs. However, any organism that gains access to the urinary tract system may cause infection, including fungi (Candida species) and viruses. In some instances, UTI results in recognition of an important underlying structural or neurogenic abnormality of the urinary tract.

The febrile infant or child with clinically significant bacteriuria and no other site of infection to explain the fever, even in the absence of systemic symptoms, has pyelonephritis (ie, upper UTI). Most episodes of UTI during the first year of life are pyelonephritis.

Febrile infants younger than 3 months are an important subset of children who may present with fever without a localizing source. Workup of fever in these infants should always include evaluation for UTI. The chart below details a treatment approach for febrile infants younger than 3 months with a temperature of more than 38°C.

Application of low-risk criteria and approach for Application of low-risk criteria and approach for the febrile infant. A reasonable approach for treating febrile infants younger than 3 months who have a temperature of greater than 38°C.

Children with UTIs who have voiding symptoms or dysuria, little or no fever, and no systemic symptoms, have lower cystitis. After age 2 years, UTI manifesting as cystitis is common among girls.

The site of infection is often unclear when a child with pyuria and clinically significant bacteriuria has another potential source of fever (eg, otitis media, pharyngitis).

Clinically significant urinary tract abnormalities are frequently identified using intrauterine ultrasonography. After birth, these children may incur additional kidney damage as a result of postnatal infection, but UTI is not the major cause of the kidney impairment. The major causes of impaired kidney function are developmental abnormalities.

See Urinary Tract Infection in Males and Urinary Tract Infection in Females for complete information on these topics.

Patient education

For patient education information, see Urinary Tract Infections and Bladder Control Problems.

Next

Etiology

Almost all UTIs are ascending in origin. Most infections begin in the bladder; from there, pathogens can spread up the urinary tract to the kidneys (pyelonephritis) and possibly to the bloodstream (bacteremia). Most episodes of UTI during the first year of life are pyelonephritis.

Pyelonephritis may lead to renal scarring and long-term complications, such as hypertension and chronic renal failure. (Approximately 10-30% of children with UTI develop renal scarring.)

Simple cystitis may progress to pyelonephritis. Predicting which patients will develop pyelonephritis is difficult, although evidence suggests that genetics may play a role. Bacterial infections are the most common cause of UTI, with E coli being the most frequent pathogen, causing 75-90% of UTIs. Other bacterial sources of UTI include the following:

  • Klebsiella species
  • Proteus species
  • Enterococcus species
  • Staphylococcus saprophyticus - Especially among female adolescents and sexually active females
  • Streptococcus group B - Especially among neonates
  • Pseudomonas aeruginosa
  • Fungi (Candida species) - Especially after instrumentation of the urinary tract
  • Adenovirus - Rare

After birth, the periurethral area, including the distal urethra, becomes colonized with aerobic and anaerobic microorganisms that appear to function as a defense barrier against colonization by uropathogens.

In early childhood, enterobacteria and enterococci are part of the normal periurethral flora. Escherichia coli is the dominant gram-negative species in young girls, whereas E coli and Proteus species predominate in boys.

Studies of girls and women prone to UTI showed that periurethral colonization occurs with the specific bacterium that causes the next infection.

Infection routes and spread of pathogens

Children up to approximately age 5 years are predisposed to UTIs, partly because of periurethral colonization by E coli, enterococci, and Proteus species. These potential uropathogens usually diminish in the first year of life and are rarely found in children older than 5 years.

Urine in the proximal urethra, urinary bladder, and other proximal sites in the urinary tract is normally sterile. Because normal voiding usually results in an essentially complete washout of contaminating bacteria, successful pathogenic colonization of the urinary bladder is unlikely unless bladder defense mechanisms are impaired. Therefore, disturbance of the normal periurethral flora predisposes a person to UTI.

Entry of bacteria into the urinary bladder can result from turbulent flow during normal voiding, voiding dysfunction, or catheterization. In addition, sexual intercourse or genital manipulation may foster the entry of bacteria into the urinary bladder. More rarely, the urinary tract may be colonized during systemic bacteremia (sepsis); this usually happens in infancy. Pathogens can also infect the urinary tract through direct spread via the fecal-perineal-urethral route.

Genetic factors

Deregulation of candidate genes in humans may predispose patients to recurrent UTIs. The identification of a genetic component may allow the identification of at-risk individuals and, therefore, prediction of genetic recurrences in their offspring.[1] Thus far, 6 genes investigated in humans may be associated with susceptibility to recurrent UTIs; these are HSPA1B, CXCR1, CXCR2, TLR2, TLR4, and TGFβ1.

As previously mentioned, evidence suggests that genetics may play a role in the progression of simple cystitis to pyelonephritis.

Risk factors

When UTI is diagnosed in a child, an attempt should be made to identify any risk factors for the UTI (eg, anatomic anomaly, voiding dysfunction, constipation).

Children who receive broad-spectrum antibiotics (eg, amoxicillin, cephalexin) that are likely to alter gastrointestinal (GI) and periurethral flora are at increased risk for UTI, because these drugs disturb the urinary tract's natural defense against colonization by pathogenic bacteria.

Prolonged incubation of bacteria in bladder urine due to incomplete bladder emptying or infrequent voiding compromises an important bladder defense against infection.

Uninhibited detrusor contractions

Symptoms of voiding dysfunction, such as urgency, frequency, hesitancy, dribbling, or incontinence, may occur in the absence of infection or local irritation, because of uninhibited detrusor contractions.

Consequently, the child may attempt to prevent incontinence during a detrusor contraction by voluntarily increasing outlet resistance. This may be achieved by using various posturing maneuvers, such as tightening of the pelvic-floor muscles, applying direct pressure to the urethra with the hands, or performing the Vincent curtsy, which consists squatting on the floor and pressing the heel of one foot against the urethra. As a result, bacteria-laden urine in the distal urethra may be milked back into the urinary bladder (urethrovesical reflux).

Neurogenic and anatomic abnormalities

Voiding dysfunction is not usually encountered in a child without neurogenic or anatomic abnormality of the bladder until the child is in the process of achieving daytime urinary control.

Constipation, with the rectum chronically dilated by feces, is an important cause of voiding dysfunction. Neurogenic or anatomic abnormalities of the urinary bladder may also cause voiding dysfunction.

Risk reduction after circumcision

Neonatal circumcision decreases the risk of UTI by about 90% in male infants during the first year of life. The risk of UTI in a circumcised infant is about 1 in 1000 during the first year, whereas an uncircumcised male infant has a 1 in 100 risk of developing a UTI.

Overall, the rate of UTIs in circumcised boys has been estimated at 0.2-0.4%, with the rate in uncircumcised boys being 5-20 times higher than in circumcised boys.

Previous
Next

Epidemiology

The incidence of UTIs varies based on age, sex, and gender. Overall, UTIs are estimated to affect 2.4-2.8% of all children every year in the United States. The international incidence of UTI is difficult to accurately assess, especially in developing countries, but is assumed to be similar to that in the United States.

Age-related demographics

Occurrences of first-time symptomatic UTI are highest in boys and girls during the first year of life and markedly decrease after that. The minimum cumulative incidence in boys and girls aged 2 years is slightly over 2%.

As many as 5% of children below age 2 years who present to the emergency department with fever have a UTI.

Sex-related demographics

During the first few months of life, the incidence of UTI in boys exceeds that in girls. By the end of the first year and thereafter, first-time and recurrent UTI are most common in girls. The prevalence of UTI in girls aged 1-2 years is 8.1%; in boys, it is 1.9%. Studies from Sweden have indicated that at least 3% of girls and 1% of boys have a symptomatic UTI by age 11 years.

Other data, however, has suggested that 8% of girls have a symptomatic UTI during childhood and that the incidence of a first-time UTI in boys older than 2 years is probably less than 0.5%. In sexually active teenaged females, the incidence of UTIs approaches 10%.

Race-related demographics

In studies by Hoberman et al, the prevalence of febrile UTI in white infants exceeded that in black infants.[2] These investigators found that 17% of white female infants younger than 1 year who were seen in an emergency department and had a temperature of 39°C or more had UTI.

Previous
Next

Prognosis

Mortality related to UTI is exceedingly rare in otherwise healthy children in developed countries. Morbidity associated with pyelonephritis is characterized by systemic symptoms such as fever, abdominal pain, vomiting, and dehydration. Bacteremia and clinical sepsis may occur. Children with pyelonephritis also may have cystitis and may develop lobar inflammation of the kidney (lobar or focal nephronia) or renal abscess. Any inflammation of the renal parenchyma may lead to scar formation.

Long-term complications of pyelonephritis are hypertension, impaired kidney function, end-stage renal disease (ESRD), and complications of pregnancy (eg, UTI, pregnancy-related hypertension, low–birth-weight neonates). Long-term complications of UTI are caused by renal damage secondary to pyelonephritis.

Cystitis may cause voiding symptoms and require antibiotics, but it is not associated with long-term, deleterious kidney damage. The voiding symptoms are usually transient, clearing within 24-48 hours of effective treatment.

In developed countries, kidney damage with long-term complications as a consequence of UTI per se is currently less common than it was in the early 20th century, when pyelonephritis was a frequent cause of hypertension and ESRD in young women. This change is probably a result of improved overall healthcare and close follow-up of children after an episode of pyelonephritis.

In countries with high-quality healthcare, hypertension, impaired renal function, and ESRD are now most commonly encountered in infants with intrauterine renal damage.

Previous
 
 
Contributor Information and Disclosures
Author

Donna J Fisher, MD  Assistant Professor of Pediatrics, Tufts University School of Medicine; Interim Chief, Division of Pediatric Infectious Diseases, Baystate Children's Hospital

Donna J Fisher, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD  Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Additional Contributors

Leslie L Barton, MD Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Ann G Egland, MD Consulting Staff, Department of Operational and Emergency Medicine, Walter Reed Army Medical Center

Ann G Egland, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Association of Military Surgeons of the US, Medical Society of Virginia, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Terrance K Egland, MD Director, Business Planning and Development, Bureau of Medicine and Surgery

Disclosure: Nothing to disclose.

Stanley Hellerstein, MD (Retired) Pediatric Nephrologist, Children's Mercy Hospital of Kansas City; (Retired) Ernest L Glasscock, MD Chair in Pediatric Research, Professor of Pediatrics, University of Missouri School of Medicine at Kansas City

Disclosure: Nothing to disclose.

David S Howes, MD Professor of Medicine and Pediatrics, Section Chief and Emergency Medicine Residency Program Director, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine

David S Howes, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Physicians-American Society of Internal Medicine, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Stephen L Thornton, MD Assistant Professor of Emergency Medicine, University of Kansas Hospital

Stephen L Thornton, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Grace M Young, MD Associate Professor, Department of Pediatrics, University of Maryland Medical Center

Grace M Young, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Emergency Physicians

Disclosure: Nothing to disclose.

References
  1. Zaffanello M, Malerba G, Cataldi L, Antoniazzi F, Franchini M, Monti E, et al. Genetic risk for recurrent urinary tract infections in humans: a systematic review. J Biomed Biotechnol. 2010;2010:321082. [Medline]. [Full Text].

  2. Hoberman A, Chao HP, Keller DM, Hickey R, Davis HW, Ellis D. Prevalence of urinary tract infection in febrile infants. J Pediatr. Jul 1993;123(1):17-23. [Medline].

  3. Zorc JJ, Levine DA, Platt SL, Dayan PS, Macias CG, Krief W, et al. Clinical and demographic factors associated with urinary tract infection in young febrile infants. Pediatrics. Sep 2005;116(3):644-8. [Medline].

  4. Shaikh N, Morone NE, Lopez J, Chianese J, Sangvai S, D'Amico F, et al. Does this child have a urinary tract infection?. JAMA. Dec 26 2007;298(24):2895-904. [Medline].

  5. [Guideline] Subcommittee on Urinary Tract Infection; Steering Committee on Quality Improvement and Management. Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months. Pediatrics. Aug 28 2011;[Medline].

  6. Girardet P, Frutiger P, Lang R. Urinary tract infections in pediatric practice. A comparative study of three diagnostic tools: dip-slides, bacterioscopy and leucocyturia. Paediatrician. 1980;9(5-6):322-37. [Medline].

  7. Goldsmith BM, Campos JM. Comparison of urine dipstick, microscopy, and culture for the detection of bacteriuria in children. Clin Pediatr (Phila). Apr 1990;29(4):214-8. [Medline].

  8. Anderson JD, Chambers GK, Johnson HW. Application of a leukocyte and nitrite urine test strip to the management of children with neurogenic bladder. Diagn Microbiol Infect Dis. Jul 1993;17(1):29-33. [Medline].

  9. Craver RD, Abermanis JG. Dipstick only urinalysis screen for the pediatric emergency room. Pediatr Nephrol. Jun 1997;11(3):331-3. [Medline].

  10. Shaw KN, McGowan KL, Gorelick MH, Schwartz JS. Screening for urinary tract infection in infants in the emergency department: which test is best?. Pediatrics. Jun 1998;101(6):E1. [Medline].

  11. Anad FY. A simple method for selecting urine samples that need culturing. Ann Saudi Med. Jan-Mar 2001;21(1-2):104-5. [Medline].

  12. Bachur R, Harper MB. Reliability of the urinalysis for predicting urinary tract infections in young febrile children. Arch Pediatr Adolesc Med. Jan 2001;155(1):60-5. [Medline].

  13. [Best Evidence] Lunn A, Holden S, Boswell T, Watson AR. Automated microscopy, dipsticks and the diagnosis of urinary tract infection. Arch Dis Child. Mar 2010;95(3):193-7. [Medline].

  14. Smolkin V, Koren A, Raz R, Colodner R, Sakran W, Halevy R. Procalcitonin as a marker of acute pyelonephritis in infants and children. Pediatr Nephrol. Jun 2002;17(6):409-12. [Medline].

  15. Nikfar R, Khotaee G, Ataee N, Shams S. Usefulness of procalcitonin rapid test for the diagnosis of acute pyelonephritis in children in the emergency department. Pediatr Int. Jul 6 2009;[Medline].

  16. Bressan S, Andreola B, Zucchetta P, Montini G, Burei M, Perilongo G, et al. Procalcitonin as a predictor of renal scarring in infants and young children. Pediatr Nephrol. Jun 2009;24(6):1199-204. [Medline].

  17. Ipek IO, Sezer RG, Kinay ES, et al. Relationship between procalcitonin levels and presence of vesicoureteral reflux during first febrile urinary tract infection in children. Urology. Jan 12 2012;[Medline].

  18. Quigley R. Diagnosis of urinary tract infections in children. Curr Opin Pediatr. Apr 2009;21(2):194-8. [Medline].

  19. Lin DS, Huang FY, Chiu NC, Koa HA, Hung HY, Hsu CH, et al. Comparison of hemocytometer leukocyte counts and standard urinalyses for predicting urinary tract infections in febrile infants. Pediatr Infect Dis J. Mar 2000;19(3):223-7. [Medline].

  20. Lin DS, Huang SH, Lin CC, Tung YC, Huang TT, Chiu NC, et al. Urinary tract infection in febrile infants younger than eight weeks of Age. Pediatrics. Feb 2000;105(2):E20. [Medline].

  21. Pennesi M, L'erario I, Travan L, et al. Managing children under 36 months of age with febrile urinary tract infection: a new approach. Pediatr Nephrol. Jan 11 2012;[Medline].

  22. Merguerian PA, Sverrisson EF, Herz DB, McQuiston LT. Urinary tract infections in children: recommendations for antibiotic prophylaxis and evaluation. An evidence-based approach. Curr Urol Rep. Mar 2010;11(2):98-108. [Medline].

  23. Downs SM. Technical report: urinary tract infections in febrile infants and young children. The Urinary Tract Subcommittee of the American Academy of Pediatrics Committee on Quality Improvement. Pediatrics. Apr 1999;103(4):e54. [Medline].

  24. Paschke AA, Zaoutis T, Conway PH, Xie D, Keren R. Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children. Pediatrics. Apr 2010;125(4):664-72. [Medline].

  25. Schnadower D, Kuppermann N, Macias CG, et al. Febrile infants with urinary tract infections at very low risk for adverse events and bacteremia. Pediatrics. Dec 2010;126(6):1074-83. [Medline].

  26. Schnadower D, Kuppermann N, Macias CG, et al. Sterile Cerebrospinal Fluid Pleocytosis in Young Febrile Infants With Urinary Tract Infections. Arch Pediatr Adolesc Med. Jul 2011;165(7):635-641. [Medline].

  27. Hoberman A, Keren R. Antimicrobial prophylaxis for urinary tract infection in children. N Engl J Med. Oct 29 2009;361(18):1804-6. [Medline].

  28. Montini G, Rigon L, Zucchetta P, Fregonese F, Toffolo A, Gobber D, et al. Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial. Pediatrics. Nov 2008;122(5):1064-71. [Medline].

  29. Garin EH, Olavarria F, Garcia Nieto V, Valenciano B, Campos A, Young L. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics. Mar 2006;117(3):626-32. [Medline].

  30. Pennesi M, Travan L, Peratoner L, Bordugo A, Cattaneo A, Ronfani L, et al. Is antibiotic prophylaxis in children with vesicoureteral reflux effective in preventing pyelonephritis and renal scars? A randomized, controlled trial. Pediatrics. Jun 2008;121(6):e1489-94. [Medline].

  31. Mattoo TK. Are prophylactic antibiotics indicated after a urinary tract infection?. Curr Opin Pediatr. Apr 2009;21(2):203-6. [Medline]. [Full Text].

  32. Craig JC, Simpson JM, Williams GJ, Lowe A, Reynolds GJ, McTaggart SJ, et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med. Oct 29 2009;361(18):1748-59. [Medline].

  33. Williams G, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev. Mar 16 2011;3:CD001534. [Medline].

  34. Ferrara P, Romaniello L, Vitelli O, Gatto A, Serva M, Cataldi L. Cranberry juice for the prevention of recurrent urinary tract infections: a randomized controlled trial in children. Scand J Urol Nephrol. 2009;43(5):369-72. [Medline].

  35. Hoberman A, Wald ER, Hickey RW, Baskin M, Charron M, Majd M, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics. Jul 1999;104(1 Pt 1):79-86. [Medline].

  36. Weisz D, Seabrook JA, Lim RK. The Presence of Urinary Nitrites Is a Significant Predictor of Pediatric Urinary Tract Infection Susceptibility to First- and Third-Generation Cephalosporins. J Emerg Med. Jul 2010;39(1):6-12.

Previous
Next
 
Application of low-risk criteria and approach for the febrile infant. A reasonable approach for treating febrile infants younger than 3 months who have a temperature of greater than 38°C.
Table 1. Urinalysis for Presumptive Diagnosis of Urinary Tract Infection*
Method Findings
Bright-field or phase-contrast microscopy of centrifuged urinary sedimentBacteria
Gram stain of uncentrifuged or centrifuged urinary sedimentBacteria
Nitrite and leukocyte esterase testPositive = UTI likely
Nitrite testPositive = UTI probable
Leukocyte esterase testPositive = Nonspecific
*Negative microscopic findings for bacteria do not rule out a UTI, nor do negative results of dipstick testing for nitrite and leukocyte esterase.
Table 2. Quantitative Urine Culture for the Diagnosis of Urinary Tract Infection*
Method Finding
Suprapubic aspirationIf a UTI is present, bacteria are likely to be proliferating in bladder urine, with growth of any organism except 2000-3000 CFU/mL coagulase-negative staphylococci.
Catheterization in a girl or midstream, clean-void collection in a circumcised boyFebrile infants and children with UTI usually have >50,000 CFU/mL of a single urinary pathogen; however, UTI may be present with 10,000-50,000 CFU/mL of a single organism.*
Midstream, clean-void collection in a girl or uncircumcised boyUTI is indicated when >100,000 CFU/mL of a single urinary pathogen is present in a symptomatic patient. Pyuria usually present. A UTI may be present with 10,000-50,000 CFU/mL of a single bacterium.*
Any method in a girl or boyIf the patient is asymptomatic, bacterial growth is usually >100,000 CFU/mL of the same organism on different days. If pyuria is absent, this result probably indicates colonization rather than infection.
*Patients with urinary frequency (ie, decreased bladder incubation time) are those most likely to have bacteria proliferating in the urinary bladder in the presence of low colony counts.
Table 3. Antibiotic Agents for Parenteral Treatment of a Urinary Tract Infection
Drug Dosage and Route Comment
Ceftriaxone50-75 mg/kg/day IV/IM as a single dose or divided q12hDo not use in infants < 6wk of age; parenteral antibiotic with long half-life; may displace bilirubin from albumin
Cefotaxime150 mg/kg/day IV/IM divided q6-8hSafe to use in infants < 6wk of age; used with ampicillin in infants aged 2-8wk
Ampicillin100 mg/kg/day IV/IM divided q8hUsed with gentamicin in neonates < 2wk of age; for enterococci and patients allergic to cephalosporins
GentamicinTerm neonates < 7 days: 3.5-5 mg/kg/dose IV q24h



Infants and children < 5y: 2.5 mg/kg/dose IV q8h or single daily dosing with normal renal function of 5-7.5 mg/kg/dose IV q24h



Children =5y: 2-2.5 mg/kg/dose IV q8h or single daily dosing with normal renal function of 5-7.5 mg/kg/dose IV q24h



Monitor blood levels and kidney function if therapy extends >48 h
Note: IM = intramuscular; IV = intravenous; q = every.
Table 4. Antibiotic Agents for the Oral Treatment of Urinary Tract Infection
Antibacterial Agent Daily Dosage
Sulfisoxazole120-150 mg/kg divided q4-6h
Sulfamethoxazole and trimethoprim6-12 mg/kg TMP, 30-60 mg/kg SMZ divided q12h
Amoxicillin and clavulanic acid20-40 mg/kg divided q8h
Cephalexin20-50 mg/kg divided q6h
Cefixime8 mg/kg divided q12-24h
Cefpodoxime10 mg/kg divided q12h
Nitrofurantoin*5-7 mg/kg divided q6h
*Nitrofurantoin may be used to treat lower UTIs. However, because of its limited tissue penetration, nitrofurantoin is not suitable for the treatment of kidney infection.
Table 5. Antibiotic Agents to Prevent Reinfection
Agent Single Daily Dose
Nitrofurantoin*1-2 mg/kg PO
Sulfamethoxazole and trimethoprim*1-2 mg/kg TMP, 5-10 mg/kg SMZ PO
Trimethoprim1-2 mg/kg PO
*Do not use nitrofurantoin or sulfa drugs in infants younger than 6 weeks. Reduced doses of an oral, first-generation cephalosporin, such as cephalexin at 10 mg/kg, may be used until the child reaches age 6 weeks. Ampicillin or amoxicillin are not recommended, because of the high incidence of resistant E coli.
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.